Role of hepcidin in the pathophysiology and diagnosis of anemia

Guido D’Angelo
Ematologia/Coagulazione, Laboratorio di Chimica-Clinica, Ematologia e Microbiologia, Azienda Ospedaliera S.Antonio Abate di Callarate, Varese, Italy

Abstract
This review summarizes the central role of hepcidin in the iron homeostasis mechanism, the molecular mechanism that can alter hepcidin expression, the relationship between hepcidin and erythropoiesis, and the pathogenetic role of hepcidin in different types of anemia. In addition, the usefulness of hepcidin dosage is highlighted, including the problems associated with analytical methods currently used as well as the measures of its molecular isoforms. Considering the central role of hepcidin in iron arrangement, it is reasonable to ponder its therapeutic use mainly in cases of iron overload. Further clinical trials are required before implementation.

Key Words
Anemia, Hepcidin, Ferroportin, Hepcidin measurement, Hepcidin agonist therapy

INTRODUCTION
Hepcidin (hepatic bactericidal protein) was initially identified as a urinary antimicrobial peptide rich in cysteine. Further studies showed that hepcidin is overexpressed in mice with iron overload and that it plays a significant role in iron homeostasis in knockout animals with iron storage disease. The complete abrogation of hepcidin entails excessive intestinal absorption of iron and increased iron release by macrophages, a condition that leads to iron overload [1-3]. Hepcidin performs its different functions via a single biochemical mechanism: hepcidin-ferroportin interaction [4]. Intestinal epithelial cells and reticuloendothelial macrophages use the same transporter, ferroportin, to transport iron in the plasma. Moreover, macrophages and enterocytes exhibit strong upregulated ferroportin expression in the erythropoietic response in an iron-restricted state.

HEPCIDIN REGULATION
Iron regulates hepcidin homeostasis. Increases in iron levels in the plasma and iron storage stimulate the production of hepcidin, which blocks iron absorption from the diet and its further storage [5]. Hepcidin production is suppressed in the case of iron deficiency; the feedback loop between iron and hepcidin should ensure the appropriate physiological concentration of iron in the plasma. Hepcidin production is also regulated by the erythropoietic process, whose core activity is characterized by high iron consumption. In this case, hepcidin suppression causes the stored iron to be released by hepatocytes and macrophages while the intestinal absorption of iron increases. This condition involves iron supplementation from hemoglobin synthesis activity [6]. Hepcidin is elevated during inflammation and/or infection. This can cause iron dysregulation with hypoferremia and anemia related to inflammatory disease [7]. Hypoferremia can also represent a strategic host defense to limit iron availability to microorganisms.

MOLECULAR MECHANISM OF HEPCIDIN REGULATION
Bone morphogenetic proteins (BMPs) are a group of growth factors that activate the transduction signal by interacting with specific receptors. They use intracellular and
extracellular iron detection mechanisms to alter hepcidin expression. BMPs increase hepcidin both in vivo and in vitro. BMP6 is the primary regulator of endogenous hepcidin. Hemojuvelin (HJV) is a BMP co-receptor specialized for iron regulation [8]. The hepcidin adjustment process in the iron response occurs in the liver on the membranes of hepatocytes. Once BMP6 binds the co-receptor HJV, the SMAD transcriptional system (SMAD1/5/8) is activated [9-11]. The activated SMAD complexes bind directly to BMP-responsive elements on the hepcidin promoter, thus inducing hepcidin transcription [12].

The TFR2 and HFE genes, which are altered in adults with hereditary hemochromatosis, appear to adjust to the detection of iron-transferrin concentration. TFR2, a TfR1 homolog, is mainly expressed in the liver. HFE is similar to major histocompatibility complex type I (MHC I) molecules. Regarding the iron-transferrin concentration complex, HFE appears to function as a shuttle between TfR1 and TFR2.

HEPCIDIN AND ERYTHROPOIESIS

Increased erythropoietic activity significantly reduces hepcidin levels. A single administration of erythropoietin (EPO) over a period of 24 hours significantly reduces hepcidin levels in humans [13]. In cases of ineffective erythropoiesis, 2 proteins are produced by erythroblasts, growth differentiation factor 15 (GDF15) and twisted gastrulation I (TWSG1), which appear to be responsible for mediating hepcidin suppression [14, 15]. EPO indirectly influences iron homeostasis. EPO production as a normal response to hypoxic stimulation is responsible for normal erythron expansion without excessive erythropoiesis. GDF15 and TWSG1 are released as a result, ultimately suppressing hepcidin synthesis as mentioned before. EPO activation is the main event that occurs in acute hypoxia; this causes the expansion of erythropoiesis, which requires adequate iron for the hemoglobinization of red cells. The production and hemoglobinization of the erythroid lineage can still occur, if hepcidin is downregulated [16, 17].

HEPCIDIN AND INFLAMMATION

Inflammation and infection increase hepcidin synthesis. Patients with sepsis, inflammatory bowel disease, myeloma, burns, and C reactive protein (CRP) levels >10 mg/dL exhibit significantly elevated hepcidin levels [3, 5, 7, 18, 19]. Macrophages are stimulated during the inflammatory process; the stimulation depends on the severity of inflammation. Activated macrophages release a network of cytokines. Among them is interleukin-6 (IL-6) is one of the primary inducers of hepcidin expression; an increase in hepcidin levels finally results in hypoferremia (Fig. 1). Hepcidin inhibits iron release from macrophages as well as intestinal iron absorption. In inflammatory states, hepcidin production is no longer regulated by iron burden (i.e., if the iron level is low, hepcidin synthesis should be downregulated) but is rather increased through IL-6 stimulation. Serum iron was demonstrated to affect hepcidin synthesis in healthy volunteers, in whom the early presence of hepcidin in the urine was measured after an oral iron administration dose that did not affect iron storage. Serum iron is an induction
signal for hepcidin production and affects serum transferrin saturation percentage. In the case of inflammation, hepcidin can also be produced by myeloid cells via the activation of TRL4, a receptor located on the membranes of neutrophils and macrophages [20].

HEPCIDIN AND ANEMIA

Understanding the physiological processes of hepcidin has made it possible to redefine the pathogenetic mechanisms of anemia.

1. Iron deficiency anemia

In pure iron deficiency anemia (IDA), serum and urinary hepcidin concentrations are significantly decreased and are even undetectable by some methods currently in use. Even in the absence of anemia, hepcidin appears to be a sensitive indicator of iron deficiency. Moreover, compared to hematocrit or hemoglobin, a decrease in hepcidin is an early marker of iron deficiency together with transferrin saturation and decreased ferritin. Since hepcidin in the urine may also be measured, samples can be collected easily from babies and children.

2. Iron-refractory iron deficiency anemia

Iron-refractory iron deficiency anemia (IRIDA) is a genetically transmitted hypochromic microcytic anemia. It is characterized by increased hepcidin production due to a gene mutation in the suppressor matriptase-2 (TMPPRSS6). Extracellular BMP2, BMP4, and BMP6 bind to the co-membrane receptor m-HJV as well as BMP receptor (BMPR). This condition triggers the phosphorylation of SMAD1, SMAD5, and SMAD8 as well as the formation of heteromeric complexes with SMAD4 as the common mediator. After nuclear translocation, heteromeric SMAD complexes stimulate the transcription of the Hamp gene, which is responsible for hepcidin production. Hepcidin transcription is negatively regulated by soluble HJV (s-HJV), which acts as an antagonist of the BMP pathway, competing with m-HJV for BMP ligands. When matriptase-2 is mutated, hepcidin increases, resulting in the chronic inhibition of iron absorption and consequent anemia [21-23].

3. Anemia with iron overload

In β-thalassemia and congenital dyserythropoietic anemia, anemia is characterized by iron overload. Patients who do not receive transfusions have greatly reduced serum and urinary hepcidin levels. Increased erythropoietic activity and the lack of hepcidin adjustment due to the iron overload suppress the signal for the production of hepcidin itself. In ineffective erythropoiesis syndromes, the suppression of hepcidin production is regulated by GDF15 and TWSG1 [1, 14, 15]. Hepcidin levels are much higher in chronically transfused patients than in non-transfused patients due to iron overload and ineffective erythropoiesis [24-26]. In non-transfused thalassemic patients, iron is stored in hepatocytes rather than macrophages, similar to that in transfused thalassemic patients. The consequence of this different iron cellular distribution is that serum ferritin is much lower in non-transfused patients and does not adequately reflect liver iron storage.

4. Anemia of chronic disease/inflammation

Patients with infections, chronic inflammatory disorders, and cancers have “anemia of chronic disease/inflammation” (ACD) [27]. Hepcidin is elevated in the following inflammatory conditions: rheumatic diseases [3], inflammatory bowel disease [18], chronic infections [3], multiple myeloma [19], and critical disorders.

There is a rare form of iron-refractory hyposideremic anemia generally present in hepatic adenoma. The early removal
of the adenoma resolves the hypoferremia and the consequent anemia, probably because the tumor is the cause of autonomous hepcidin production.

Obesity can also be considered a chronic inflammatory state that can cause hyposideremia [28]. In both anemia and hyposideremia, the elevated hepcidin level helps differentiate ACD from IDA. A condition of "mixed anemia" can arise in chronic inflammatory diseases involving bleeding and/or malnutrition. Under these conditions, the hyposideremia could counteract the hepcidin increase mediated by inflammation. A true iron deficiency from non-intestinal absorption by hepcidin may develop when inflammation is present for years.

5. Anemia in chronic kidney disease

In patients with anemia in chronic kidney disease (CKD), the anemia is mainly due to the lack of EPO. Kidney function (i.e., excretion) plays an important role in hepcidin clearance. Kidney dysfunction results in decreased hepcidin clearance and consequent hepcidin storage with hyposideremic anemia development [29]. As CKD progresses, hepcidin level increases regardless of the inflammatory state. Hepcidin production may be considered to mirror genetic hemochromatosis and chronic diseases (Fig. 2) [30]. Hemochromatosis is characterized by low hepcidin production, which increases intestinal absorption of iron and iron release by macrophages. This inevitably leads to progressive iron storage in tissues. In chronic diseases, high hepcidin production inhibits iron release from macrophages and intestinal absorption of iron. This consequently induces an anemic condition. The interaction between hepcidin and ferroportin determines the plasma iron transport. Hepcidin concentration is regulated by iron, erythropoietic activity, and inflammation [31].

| Type of anemia                        | Hepcidin level | Transferrin saturation | Ferritin | Soluble transferrin receptor |
|--------------------------------------|----------------|------------------------|----------|------------------------------|
| Iron deficiency anemia (IDA)         | Low            | Low                    | Low      | Increased                   |
| Iron-refractory iron deficiency anemia (IRIDA) | High           | Low                    | Low      | Variable                    |
| Anemia with iron overload            | Low (not transfused) | High                   | High     | Variable                    |
| Anemia of chronic disease/inflammation (ACD) | High           | Low                    | Normal or High | Normal                   |
| Mixed anemia                         | Normal         | Low                    | Low      | Normal or High              |
| Anemia in chronic kidney disease (ACKD) | High           | Variable               | Variable | Variable                    |
| Resistance to erythropoietin         | High           | Variable               | Variable | Variable                    |

Since approximately 90% of circulating hepcidin is linked to α2-macroglobulin, it is important to consider whether it is necessary to measure total or unbound hepcidin and which current valuation methods can be used. The difference between immunochemical (IC) methods and mass spectrometry is another important issue. IC methods cannot selectively distinguish hepcidin-22 and hepcidin-25 from hepcidin-20. However, the reasons for including hepcidin-20 and hepcidin-22 in the total hepcidin level for determining different iron-related diseases remain unclear. The coefficient of variation among samples is lower for the plasma hepcidin assay than that for urinary hepcidin. This suggests that the difference between measured levels in the urine and plasma is not due to the method used, but due to biological mechanisms such as excretion. Hepcidin levels measured using different methods vary considerably, but the analytical variance is low and similar for other methods in general.

In order to harmonize the various methods used to measure hepcidin, it is recommended to introduce internal standards for all basic mass spectrometry methods used for clinical trials, reach assigned consensus levels, adjust the levels of calibrators used in each procedure, produce a calibrator that mimics a patient’s serum, periodically analyze shared samples and/or interchangeable calibrators, and have a value assigned for quality control.

In addition to measuring hepcidin, it is possible to measure prohepcidin. However, the measurement of the latter does not appear to be biologically relevant with respect to...
immune-mediated activities of T-cells [37, 38]. Such inhibition could be caused not only by erythropoiesis inhibitors may be effective for inducing hepcidin inhibition; and improve anemia in some cases [40, 41]. Hydroxyproline has been shown to suppress hepcidin production activity concentration [39]. The use of anticytokines such as anti-IL-6 as a BMP signal antagonist, decreasing the basal concentration of the BMP signal, have been tested. Even soluble HJV acts with a framework of IDA or systemic IDA.

Patients with diseases that cause hepcidin excess and occur with iron storage. Hepcidin antagonists could be used in non-transfused patients with diseases that cause hepcidin excess and occur with a framework of IDA or systemic IDA.

Other drugs targeting the regulation of the hepcidin system, such as dorsomorphin, a small molecule that inhibits the BMP signal, have been tested. Even soluble HJV acts as a BMP signal antagonist, decreasing the basal concentration of hepcidin in mice while increasing the liver iron concentration [39]. The use of anticytokines such as anti-IL-6 has been shown to suppress hepcidin production activity and improve anemia in some cases [40, 41]. Hydroxyproline inhibitors may be effective for inducing hepcidin inhibition; such inhibition could be caused not only by erythropoiesis stimulation but also by the ability of hydroxyproline inhibitors to interfere with the transcriptional complex, hypoxia-inducible factor [42].

Possible Therapeutic Application of Hepcidin Agonists

Having established the central role of hepcidin in iron homeostasis, it is possible to consider its use as a novel treatment for anemia. Under particular conditions of chronic inflammation, despite low plasma iron levels, iron treatment can be harmful because it can trigger the growth of pathogens and/or contribute to neoplastic transformation because of its ability to unbalance immune functions, particularly the immune-mediated activities of T-cells [37, 38].

Although hepcidin is not used for therapeutic purposes at present, there are some ongoing studies on selected patients. Hepcidin agonists could be used to prevent or improve the accumulation of iron in both transfused and non-transfused β-thalassemic patients and even in anemia with iron storage. Hepcidin antagonists could be used in patients with diseases that cause hepcidin excess and occur with a framework of IDA or systemic IDA.

Other drugs targeting the regulation of the hepcidin system, such as dorsomorphin, a small molecule that inhibits the BMP signal, have been tested. Even soluble HJV acts as a BMP signal antagonist, decreasing the basal concentration of hepcidin in mice while increasing the liver iron concentration [39]. The use of anticytokines such as anti-IL-6 has been shown to suppress hepcidin production activity and improve anemia in some cases [40, 41]. Hydroxyproline inhibitors may be effective for inducing hepcidin inhibition; such inhibition could be caused not only by erythropoiesis stimulation but also by the ability of hydroxyproline inhibitors to interfere with the transcriptional complex, hypoxia-inducible factor [42].

Conclusions

Iron-related diseases are common and clinically important. Recent research on both hepcidin and the key role of the hepcidin-ferroportin axis has clarified the pathogenesis of IDA, ACD, and anemia with iron overload. This knowledge will allow the development of new tests and possibly new treatments as well.

Authors’ Disclosures of Potential Conflicts of Interest

No potential conflicts of interest relevant to this article were reported.

References

1. Weinstein DA, Roy CN, Fleming MD, Loda MF, Wolfsdorf JJ, Andrews NC. Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood 2002;100:3776-81.
2. Nicolas G, Chauvet C, Viatte L, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002;110:1037-44.
3. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative modulator of anemia of inflammation, is a type II acute-phase protein. Blood 2003;101:2461-3.
4. Bergamaschi G, Villani L. Serum hepcidin: a novel diagnostic tool in disorders of iron metabolism. Haematologica 2009;94:1631-3.
5. Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassay for human serum hepcidin. Blood 2008;112:4292-7.
6. Pak M, Lopez MA, Gabayan V, Ganz T, Rivera S. Suppression of hepcidin during anemia requires erythropoietic activity. Blood 2006;108:3730-5.
7. Ganz T. Molecular pathogenesis of anemia of chronic disease. Pediatr Blood Cancer 2006;46:554-7.
8. Babitt JL, Huang FW, Wrighting DM, et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet 2006;38:531-9.
9. Andriopoulos B Jr, Corradini E, Xia Y, et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet 2009;41:482-7.
10. Meynard D, Kautz L, Darnaud V, Canonne-Hergaux F, Coppin H, Roth MP. Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat Genet 2009;41:478-81.
11. Xia Y, Babitt JL, Sidu Y, Chung RT, Lin HY. Hemojuvelin regulates hepcidin expression via a selective subset of BMP ligands and receptors independently of neogenin. Blood 2008;111:5195-204.
12. Babitt JL, Lin HY. Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. Am J Kidney Dis 2010;55:726-41.
13. Ashby DR, Gale DP, Busbridge M, et al. Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin. Haematologica 2010;95:505-8.
14. Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007;13:1096-101.
15. Tanno T, Purayette P, Sriripichai O, et al. Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood 2009;114:181-6.
16. Piperno A, Galimberti S, Mariani R, et al. Modulation of hepcidin production during hypoxia-induced erythropoiesis in humans in vivo: data from the HIGHCARE project. Blood 2011;117:2953-9.
17. Peyssonnaux C, Zinkernagel AS, Schuepbach RA, et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest 2007;117:1926-32.
18. Semrin G, Fishman DS, Bousvaros A, et al. Impaired intestinal iron absorption in Crohn’s disease correlates with disease activity and markers of inflammation. Inflamm Bowel Dis 2006;12:1101-6.
Role of hepcidin in anemia

19. Sharma S, Nemeth E, Chen YH, et al. Involvement of hepcidin in the anemia of multiple myeloma. Clin Cancer Res 2008;14:3262-7.
20. Peyssonaux A, Zinkernagel AS, Datta V, Lauth X, Johnson RS, Nizet V. TLR4 dependent hepcidin expression by myeloid cells in response to bacterial pathogens. Blood 2006;107:3727-32.
21. Ramsay AJ, Hooper JD, Folgueras AR, Velasco G, Lopez-Otin C. Matriptase-2 (TMPRSS6): a proteolytic regulator of iron homeostasis. Haematologica 2009;94:840-9.
22. Melis MA, Cau M, Congiu R, et al. A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron. Haematologica 2008;93:1473-9.
23. Ramsay AJ, Hooper JD, Folgueras AR, Velasco G, Lopez-Otin C. Matriptase-2 (TMPRSS6): a proteolytic regulator of iron homeostasis. Haematologica 2009;94:840-9.
24. Kearney SL, Nemeth E, Neufeld EJ, et al. Urinary hepcidin in congenital chronic anemias. Pediatr Blood Cancer 2007;48:57-63.
25. Nemeth E, Ganz T. Hepcidin and iron-loading anemias. Haematologica 2006;91:727-32.
26. Orga R, Galanello R, Ganz T, et al. Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica 2007;92:583-8.
27. Cartwright GE. The anemia of chronic disorders. Semin Hematol 1966;3:351-75.
28. Tussing-Humphreys LM, Liang H, Nemeth E, Freels S, Braunschweig CA. Excess adiposity, inflammation, and iron-deficiency in female adolescents. J Am Diet Assoc 2009;109:297-302.
29. Zaritsky J, Young B, Wang HJ, et al. Hepcidin-a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol 2009;4:1051-6.
30. De Domenico I, Ward DM, Kaplan J. Hepcidin regulation: ironing out the details. J Clin Invest 2007;117:1755-8.
31. Nemeth E. Targeting the hepcidin-ferroportin axis in the diagnosis and treatment of anemias. Adv Hematol 2010;2010:750643.
32. Busbridge M, Griffiths C, Ashby D, et al. Development of a novel immunoassay for the iron regulatory peptide hepcidin. Br J Biomed Sci 2009;66:150-7.
33. Kemna EH, Tjalsma H, Podust VN, Swinkels DW. Mass spectrometry-based hepcidin measurements in serum and urine: analytical aspects and clinical implications. Clin Chem 2007;53:620-8.
34. Bansal SS, Halket JM, Fusova J, et al. Quantification of hepcidin using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 2009;23:1531-42.
35. Kroo TJ, Kemna EH, Bansal SS, et al. Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization. Haematologica 2009;94:1748-52.
36. Kroo TJ, Hendriks JC, Laarakers CM, et al. (Pre)analytical imprecision, between-subject variability, and daily variations in serum and urine hepcidin: implications for clinical studies. Anal Biochem 2009;389:124-9.
37. Weiss G. Iron, infection and anemia-a classical triad. Wien Klin Wochenschr 2002;114:357-67.
38. Weiss G. Pathogenesis and treatment of anaemia of chronic disease. Blood Rev 2002;16:87-96.
39. Babitt JL, Huang FW, Xia Y, Sidis Y, Andrews NC, Lin HY. Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest 2007;117:1933-9.
40. Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005;106:2627-32.
41. Kawabata H, Tomosugi N, Kanda J, Tanaka Y, Yoshizaki K, Uchiyama T. Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman’s disease. Haematologica 2007;92:857-8.
42. Klaus S, Arend M, Fourney P, et al. Induction of erythropoiesis and iron utilization by the HIF prolyl hydroxylase inhibitor FG-4592. J Am Soc Nephrol 2005;16(Suppl):49A(abstr 050).